ROIV’s mosliciguat advances to phase 3 in PH-ILD

Mosliciguat showed a 56.3% reduction in PVR and improvements in 6MWD and NT-proBNP in PH-ILD patients, with favorable safety and once-daily dosing. A phase 3 trial is underway to evaluate efficacy and safety further.